Skip to main content
. 2017 Jul 17;35(26):3010–3020. doi: 10.1200/JCO.2017.72.8519

Fig 4.

Fig 4.

(A) Progression-free survival and (B) overall survival in patients who cleared disease from bone marrow 4 weeks after CAR-T cell infusion by flow cytometry and had no detectable malignant IGH copies (IGHseq-negative) compared with those who had detectable malignant IGH copies (IGHseq-positive). mOS, median OS; mPFS, median PFS; NR, not reached.